STOCK TITAN

Protagonist Therapeutics Inc - PTGX STOCK NEWS

Welcome to our dedicated news page for Protagonist Therapeutics (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Protagonist Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Protagonist Therapeutics's position in the market.

Rhea-AI Summary
Protagonist Therapeutics, Inc. (PTGX) issued inducement awards to Vice President Sid Reddy, granting him options to purchase 25,000 shares at an exercise price of $28.23. The shares vest over four years, with 25% vesting on the first anniversary of hire and the rest monthly over three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Protagonist Therapeutics, Inc. announced the successful Phase 2b clinical trial of JNJ-2113 in adults with moderate-to-severe plaque psoriasis, achieving primary and secondary endpoints with PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively. The study showed a dose-ordered response in patients treated with JNJ-2113, with 79 percent of patients achieving a PASI-75 response at Week 16. The publication in the New England Journal of Medicine (NEJM) reflects the robust efficacy of JNJ-2113, currently being evaluated in multiple Phase 3 psoriasis studies in the ICONIC-program. The study also demonstrated improvements in patient-reported outcomes and a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
clinical trial
-
Rhea-AI Summary
Takeda and Protagonist Therapeutics, Inc. announced a worldwide license and collaboration agreement for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide for the treatment of Polycythemia Vera. Protagonist will receive a $300 million upfront payment and is eligible for additional milestone payments and royalties. Takeda will lead the ex-U.S. commercialization, while Protagonist will handle U.S. development and regulatory approval. The partnership combines Protagonist's peptide drug development expertise with Takeda's commercial capabilities in rare hematology. The deal aims to address the significant unmet need of PV patients and leverage Takeda's 70-year legacy of innovation in rare diseases. Rusfertide's mechanism of action regulates iron homeostasis and has shown positive results in the Phase 2 trial. The agreement allows Protagonist to focus on Phase 3 completion while sharing profits with Takeda in the U.S. market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.03%
Tags
none
Rhea-AI Summary
Protagonist Therapeutics, Inc. announced that their CEO will participate in a fireside chat at the 6th Annual Guggenheim Healthcare Talks Annual Biotechnology Conference in New York City on February 7-8, 2024. The presentation will take place on February 8 at 9:00-9:25 A.M. EST at St. Regis New York. A replay of the presentation will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.78%
Tags
conferences
-
Rhea-AI Summary
Protagonist Therapeutics, Inc. (PTGX) announced that its President and CEO, Dinesh V. Patel, Ph.D., will participate in a presentation and host one-on-one meetings with investors at the 42nd Annual J.P. Morgan Healthcare Conference on January 8-11, 2024. The presentation will take place on Tuesday, January 9 at 9:45-10:25 A.M. PST in San Francisco, CA. The event details and webcast link can be found on the company's corporate website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.71%
Tags
conferences
-
Rhea-AI Summary
Protagonist Therapeutics, Inc. (PTGX) announced it has earned a $10 million milestone payment following the dosing of the third patient in ANTHEM-UC, a Phase 2b trial to evaluate the safety and effectiveness of JNJ-2113 compared with placebo in participants with moderately to severely active ulcerative colitis. With this additional payment, the Company has now earned $60 million in payments in the fourth quarter of 2023 for milestones achieved in the JNJ-2113 Phase 2b and Phase 3 clinical programs led by the Company's collaboration partner, Janssen Biotech, Inc., a Johnson & Johnson company. The Company remains eligible for up to an additional $795 million in other development and sales milestone payments with respect to JNJ-2113 or other licensed IL-23 receptor antagonist oral peptides.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
clinical trial
Rhea-AI Summary
Protagonist Therapeutics, Inc. (PTGX) presented long-term follow-up data from the REVIVE Phase 2 study and other analyses at the American Society of Hematology 2023 Annual Meeting. The data showed durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia vera. Rusfertide, a mimetic of the natural hormone hepcidin, demonstrated potential therapeutic value in treating PV and other diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
-
Rhea-AI Summary
Protagonist Therapeutics, Inc. (PTGX) announced the addition of two Phase 3 studies, ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2, evaluating JNJ-2113 in head-to-head comparisons against deucravacitinib in patients with moderate-to-severe psoriasis. The company is eligible to receive a $115 million milestone payment upon achieving co-primary endpoints in any of the studies. JNJ-2113 is a targeted oral peptide designed to selectively block the IL-23 receptor, and the Phase 3 program aims to establish it as the preferred oral treatment option for psoriasis patients. Protagonist has a license and collaboration agreement with Janssen for the development and commercialization of JNJ-2113, earning milestone payments upon successful milestones and eligible for additional development and sales milestone payments. The company also retains upward tiering royalties of 6%-10% for net sales of JNJ-2113.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
clinical trial
-
Rhea-AI Summary
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) issued inducement awards to two new employees, granting them options to purchase 50,000 shares of the company's common stock at an exercise price of $16.29. The options vest over a four-year period, with 25% vesting on the first anniversary of hire and the remainder in equal monthly installments over three years. The awards were granted in accordance with the Protagonist Therapeutics Amended and Restated Inducement Plan and approved by the compensation committee as a material inducement to employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.28%
Tags
none
Rhea-AI Summary
Protagonist Therapeutics (Nasdaq:PTGX) ranked in the top 3% of the 2023 Deloitte Technology Fast 500TM, showcasing impressive revenue growth fueled by a novel oral peptide therapeutic program. The company's CEO expressed pride in the recognition and highlighted the dedication of the team and strength of partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.82%
Tags
none
Protagonist Therapeutics Inc

Nasdaq:PTGX

PTGX Rankings

PTGX Stock Data

1.57B
39.78M
1.82%
101.63%
4.53%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Newark

About PTGX

protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist